Ogiso, Y <br/><br/>
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.  [electronic resource] 

 -  Cancer research  May 2000 
 - 2429-34 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylcysteine--analogs & derivatives<br/>Animals<br/>Antigens, Neoplasm<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Agents, Phytogenic--pharmacology<br/>Blotting, Northern<br/>Cell Cycle--drug effects<br/>Cysteine Endopeptidases--metabolism<br/>Cysteine Proteinase Inhibitors--pharmacology<br/>DNA Topoisomerases, Type II--biosynthesis<br/>DNA-Binding Proteins<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--pharmacology<br/>Etoposide--pharmacology<br/>Glucose--metabolism<br/>Humans<br/>Hypoxia<br/>Immunoblotting<br/>Isoenzymes--antagonists & inhibitors<br/>Methotrexate--pharmacology<br/>Mice<br/>Mice, Nude<br/>Multienzyme Complexes--metabolism<br/>Neoplasm Transplantation<br/>Nucleic Acid Synthesis Inhibitors--pharmacology<br/>Proteasome Endopeptidase Complex<br/>Time Factors<br/>Topoisomerase II Inhibitors<br/>Tumor Cells, Cultured<br/>Vincristine--pharmacology